Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have earned a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $29.56.
Several research firms recently issued reports on HRTX. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Oppenheimer set a $27.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. Mizuho restated a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research report on Friday, December 8th. Cowen reiterated a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 6th. Finally, ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th.
Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.70 during midday trading on Monday, hitting $18.35. The company had a trading volume of 1,599,300 shares, compared to its average volume of 854,587. The stock has a market cap of $1,132.76, a PE ratio of -4.84 and a beta of 2.13. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $18.65.
A number of large investors have recently made changes to their positions in HRTX. Legal & General Group Plc raised its stake in shares of Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the last quarter. Quantbot Technologies LP increased its position in Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the last quarter. Trexquant Investment LP purchased a new stake in Heron Therapeutics during the third quarter valued at $206,000. Jane Street Group LLC purchased a new stake in Heron Therapeutics during the third quarter valued at $223,000. Finally, HighTower Advisors LLC increased its position in Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 98.78% of the company’s stock.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics and related companies.